Sareum Hldgs Plc

LSE SAR
ยฃ22.00 0.0000 0.0000%
์˜ค๋Š˜ ์ฃผ๊ฐ€
์˜๊ตญ
์ ‘๊ทผ ๊ถŒํ•œ์„ ์–ป๋‹ค
Finrange ์ฃผ์‹ ๋“ฑ๊ธ‰์—
์ด ์š”๊ธˆ์ œ๋ฅผ ์ด์šฉํ•˜๋ฉด ์ œํ•œ ์—†์ด ์„œ๋น„์Šค๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ชจ๋“  ์ •๋ณด๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์–ป๋‹ค 7์ผ ๋ฌด๋ฃŒ

๋“ฑ๊ธ‰ ํ•€ ๋ฒ”์œ„

์ƒ‰์ธ: 8.75 %
Market cap ์‹œ๊ฐ€์ด์•ก โ€“ ํšŒ์‚ฌ์˜ ๋ชจ๋“  ์ฃผ์‹ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ์ด๋Š” ํŠน์ • ์ฃผ์‹์˜ ๊ฐ€๊ฒฉ์— ๋ฐœํ–‰ ์ฃผ์‹์ˆ˜๋ฅผ ๊ณฑํ•˜์—ฌ ๊ณ„์‚ฐ๋ฉ๋‹ˆ๋‹ค.
1.98B
EV ๊ธฐ์—… ๊ฐ€์น˜๋Š” ํšŒ์‚ฌ์˜ ์ด ๊ฐ€์น˜๋ฅผ ์ธก์ •ํ•œ ๊ฒƒ์œผ๋กœ, ์ข…์ข… ์ฃผ์‹ ์‹œ๊ฐ€์ด์•ก์— ๋Œ€ํ•œ ๋ณด๋‹ค ํฌ๊ด„์ ์ธ ๋Œ€์•ˆ์œผ๋กœ ์‚ฌ์šฉ๋ฉ๋‹ˆ๋‹ค. ๊ธฐ์—… ๊ฐ€์น˜์—๋Š” ํšŒ์‚ฌ์˜ ์‹œ๊ฐ€์ด์•ก๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๋‹จ๊ธฐ ๋ฐ ์žฅ๊ธฐ ๋ถ€์ฑ„์™€ ํšŒ์‚ฌ ๋Œ€์ฐจ๋Œ€์กฐํ‘œ์˜ ํ˜„๊ธˆ๋„ ํฌํ•จ๋ฉ๋‹ˆ๋‹ค.
-
Beta ๋ฒ ํƒ€๋Š” ๊ฐ€์žฅ ๋„๋ฆฌ ์‚ฌ์šฉ๋˜๋Š” ์œ„ํ—˜ ์ง€ํ‘œ ์ค‘ ํ•˜๋‚˜์ด๋ฉฐ ํ†ต๊ณ„์  ์ฒ™๋„์ž…๋‹ˆ๋‹ค. ๋ถ„์„๊ฐ€๋“ค์€ ์ฃผ์‹์˜ ์œ„ํ—˜ ํ”„๋กœํ•„์„ ๊ฒฐ์ •ํ•ด์•ผ ํ•  ๋•Œ ์ด ์ฒ™๋„๋ฅผ ์ž์ฃผ ์‚ฌ์šฉํ•ฉ๋‹ˆ๋‹ค.
-
Shares ๋ฐœํ–‰ ์ฃผ์‹์ˆ˜๋Š” ๊ธฐ๊ด€ ํˆฌ์ž์ž๊ฐ€ ๋ณด์œ ํ•œ ์ฃผ์‹ ๋ธ”๋ก๊ณผ ํšŒ์‚ฌ ๋‚ด๋ถ€์ž๊ฐ€ ์†Œ์œ ํ•œ ์ œํ•œ๋œ ์ฃผ์‹์„ ํฌํ•จํ•˜์—ฌ ํ˜„์žฌ ๋ชจ๋“  ์ฃผ์ฃผ๊ฐ€ ๋ณด์œ ํ•˜๊ณ  ์žˆ๋Š” ํšŒ์‚ฌ์˜ ์ฃผ์‹์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.
124.83M
YTD ์—ฐ์ดˆ(YTD)๋Š” ๊ธˆ๋…„ ๋˜๋Š” ํšŒ๊ณ„์—ฐ๋„์˜ ์ฒซ๋‚ ๋ถ€ํ„ฐ ํ˜„์žฌ ๋‚ ์งœ๊นŒ์ง€์˜ ๊ธฐ๊ฐ„์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ๊ทธ ์•ฝ์–ด๋Š” ์ข…์ข… ํˆฌ์ž ์ˆ˜์ต ๋ฐ ๊ฐ€๊ฒฉ ๋ณ€ํ™”์™€ ๊ฐ™์€ ๊ฐœ๋…์„ ์ˆ˜์ •ํ•ฉ๋‹ˆ๋‹ค.
-10.20 %

๋‹ค๊ฐ€์˜ค๋Š” ์ด๋ฒคํŠธ Sareum Hldgs Plc

๋ชจ๋“  ์ด๋ฒคํŠธ
์˜ˆ์ •๋œ ํ–ฅํ›„ ์ด๋ฒคํŠธ๊ฐ€ ์—†์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ฐจํŠธ Sareum Hldgs Plc

์ฃผ์‹๋ถ„์„ Sareum Hldgs Plc

์ง€์‹œ์ž ํšŒ์‚ฌ ์‚ฐ์—…
P/E (LTM) ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํšŒ์‚ฌ์— ๋Œ€ํ•œ ํˆฌ์ž์ž์˜ ํˆฌ์ž๊ฐ€ ๋ช‡ ๋…„ ๋™์•ˆ ์ด์ต์œผ๋กœ ๋ณด์ƒ๋˜๋Š”์ง€ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค.
- -489.89
P/BV (LTM) ํ˜„์žฌ ์žฅ๋ถ€๊ฐ€์น˜์— ๋Œ€ํ•œ ์ฃผ์‹์˜ ์‹œ์žฅ ๊ฐ€๊ฒฉ ๋น„์œจ์„ ํ‘œ์‹œํ•ฉ๋‹ˆ๋‹ค.
938.66 518.85
EV/EBITDA (LTM) ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํšŒ์‚ฌ ๊ฐ€์น˜์™€ ์„ธ์ „ EBITDA์˜ ๋น„์œจ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
- -1468.12
Net Debt/EBITDA (LTM) ํšŒ์‚ฌ์˜ ๋ถ€์ฑ„ ๋น„์œจ์€ ํšŒ์‚ฌ๊ฐ€ ๋ถ€์ฑ„๋ฅผ ์ƒํ™˜ํ•˜๊ธฐ ์œ„ํ•ด ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํ˜„๊ธˆ ํ๋ฆ„์„ ์–ผ๋งˆ๋‚˜ ์˜ค๋žซ๋™์•ˆ ์šด์˜ํ•ด์•ผ ํ•˜๋Š”์ง€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
- 0.36
ROE (LTM) ํšŒ์‚ฌ์˜ ์ฃผ์‹ ์ž๋ณธ ์‚ฌ์šฉ ํšจ์œจ์„ฑ์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค. ์ฆ‰, ROE๋Š” ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํˆฌ์žํ•œ ์ž๋ณธ์— ๋Œ€ํ•œ ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์ด ์–ผ๋งˆ์ธ์ง€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
- -194.13

์—ฐ๊ฐ„ ๊ฐ€๊ฒฉ ๋ณ€๋™ Sareum Hldgs Plc

11.25ยฃ 31.00ยฃ
์ตœ์†Œ ๋งฅ์Šค

์š”์•ฝ ๋ถ„์„ Sareum Hldgs Plc

์ ‘๊ทผ ๊ถŒํ•œ์„ ์–ป๋‹ค
Finrange ์ฃผ์‹ ๋“ฑ๊ธ‰์—
์ด ์š”๊ธˆ์ œ๋ฅผ ์ด์šฉํ•˜๋ฉด ์ œํ•œ ์—†์ด ์„œ๋น„์Šค๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ชจ๋“  ์ •๋ณด๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์–ป๋‹ค 7์ผ ๋ฌด๋ฃŒ

์ฃผ์ฃผ๊ตฌ์กฐ Sareum Hldgs Plc

์ˆ˜์ต ๋ฐ ์ˆœ์ด์ต Sareum Hldgs Plc

๋ชจ๋“  ๋งค๊ฐœ๋ณ€์ˆ˜

ํšŒ์‚ฌ์†Œ๊ฐœ Sareum Hldgs Plc

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. Sareum Holdings plc was formerly known as Keepfast plc and changed its name to Sareum Holdings plc in July 2004. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
์ฃผ์†Œ:
Langford Arch, Cambridge, United Kingdom, CB22 3FX
ํšŒ์‚ฌ ์ด๋ฆ„: Sareum Hldgs Plc
๋ฐœํ–‰์ž ํ‹ฐ์ปค: SAR
ISIN: GB00BMC3RJ87
๊ตญ๊ฐ€: ์˜๊ตญ
๊ตํ™˜: LSE
ํ†ตํ™”: ยฃ
IPO ๋‚ ์งœ: 2004-10-11
๋Œ€์ง€: https://www.sareum.com